In an interview with Reuters yesterday, CEO Pascal Soriot warned that turning around AstraZeneca is going to require a lengthy rebuilding effort.
Over the next three years the pharma company plans to build a $500 million complex on an 11-acre site at the Cambridge BioMedical Campus.
Over the next three years the pharma company plans to build a $500 million complex on its new campus that will house its U.K. operations for biologics and small molecule research as well as the corporate staff now operating in London.
The 2013-14 flu season is set to be the most closely watched in years. In February, FDA cleared the use of quadrivalent vaccines which protect against two A and two B strains. GlaxoSmithKline and AstraZeneca began gearing up, and Sanofi will now join them too.
In its $1.15 billion buyout of Pearl Therapeutics this week, AstraZeneca bolstered its late-stage drug development with a Phase III inhaled delivery platform to treat respiratory diseases.
AstraZeneca's announcement early this year that Peter Greenleaf would be "promoted" from the head of MedImmune to the top job in the company's big Latin American division raised a few eyebrows around the industry.
AstraZeneca's first-quarter earnings report was a stark indication of why its new CEO Pascal Soriot is scrambling to buy some new drugs the company can lean on.
AstraZeneca ($AZN) has beefed up its lineup of software vendors for its virtual neuroscience group. A provider of clinical trials software, ePharmaSolutions plans to support AZ's neuroscience group with study apps and cloud computing.
AstraZeneca is piecing together a team of contractors for its almost virtual neuroscience unit, and the company has signed up with ePharmaSolutions to create a network that will unite its many outsourcers.
The Pearl Therapeutics buyout gives AstraZeneca's late-stage development director Briggs Morrison a Phase III respiratory therapy just days after the pharma giant was forced to throw in the towel on the rheumatoid arthritis drug fostamatinib.